Australia’s Food and Beverage Company, Retail Food Group Ltd (ASX: RFG), has been recently targeted by the investors with regards to its soft trading update given the challenging retail conditions. The group’s stock has been down over 48% in last one month (as at December 22, 2017). RFG stock, however, has been gaining back its lost momentum with the recent 9.13% rise on December 27, 2017; and has found support from its lenders, National Australia Bank and Westpac Bank on extension of debt facilities.

The group has lately advised that it has successfully completed negotiations to extend its three-year debt facilities of $150 million due to mature in December 2018, into longer dated maturities. Under the new agreements, which were renegotiated as part of its normal banking annual review process, RFG’s three-year debt facilities have been extended to entail $100 million extended to facilities maturing in January 2020 and $50 million extended to facilities maturing in December 2020. RFG has also reduced existing five-year debt facilities maturing in December 2020 by $25 million, with its total senior debt facilities being $319 million.

Medical Technology-related Healthcare stock, ImpediMed Ltd (ASX: IPD) zoomed up over 8% as the group announced about receiving the US FDA 510(k) clearance to market its SOZO^TM for fluid monitoring of patients in the US living with chronic heart failure (CHF). SOZO utilizes its bioimpedance spectroscopy (BIS) technology to perform a full scan of 256 frequencies to provide both detailed and accurate information on the fluid status of patients. Studies have shown detectable differences in whole-body extracellular fluid using its BIS devices as low as 0.1 litres.

With individual updates, both the above stocks have caught investors’ attention prior to new year’s week.

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.